AI Article Synopsis
- - An expert panel from the European Alliance for Personalized Medicine (EAPM) discussed progress and challenges in treating mantle cell lymphoma (MCL) in Europe over the past ten years.
- - They identified barriers to better care, such as limited access to new treatments, insufficient infrastructure and funding for testing, and a lack of necessary skills and research support.
- - The panel suggested that improvements could come through enhanced coordination between countries and changes in policy and investment at both national and EU levels.
Article Abstract
An expert panel convened by the European Alliance for Personalized Medicine (EAPM) reflected on achievements and outstanding challenges in Europe in mantle cell lymphoma (MCL). Through the prism of member state experience, the panel noted advances in outcomes over the last decade, but highlighted issues constituting barriers to better care. The list notably included availability of newer treatments, infrastructure and funding for related testing, and shortages of relevant skills and of research support. The prospect of improvements was held to reside in closer coordination and cooperation within and between individual countries, and in changes in policy and scale of investment at both national and EU levels.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498856 | PMC |
| http://dx.doi.org/10.3390/healthcare10091682 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!